ProCE Banner Activity

EVOKE-01: Phase III Trial of Sacituzumab Govitecan vs Docetaxel in Patients With Previously Treated Advanced NSCLC

Conference Coverage

The phase III EVOKE-01 trial did not show a statistically significant improvement in the primary endpoint of OS with sacituzumab govitecan vs docetaxel in patients with advanced NSCLC and progressive disease after prior chemotherapy and anti–PD-1/PD-L1 therapy. Numerical improvement trends in OS were observed, particularly in patients who did not respond to their previous anti–PD-1/PD-L1–based regimen.

Released: June 02, 2024

Expiration: June 01, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.